Clinical trial
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or…
NCT00007852 · University of Nebraska, Other · Completed
Key facts
| NCT number | NCT00007852 |
|---|---|
| Title | Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial of Rituxan and BEAM High-Dose Chemotherapy and Autologous Peripheral Blood Progenitor Transplant for Lymphoma |
| Lead sponsor | University of Nebraska, Other |
| Collaborators | National Cancer Institute (NCI) NIH Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | rituximab, carmustine, cytarabine, etoposide, melphalan, autologous hematopoietic stem cell transplantation |
| Enrollment | 44 |
| Start date | Sep 1, 2000 |
| Primary completion | Jan 1, 2002 |
| Completion | Jan 1, 2011 |
| First posted | Feb 12, 2004 |
| Last update posted | Sep 1, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: